title: Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia.
abstract: BACKGROUND
  Hyperuricemia has been associated with an increased risk of endothelial dysfunction (ED), cardiovascular and renal disease. The role of uric acid (UA) on vascular damage is still controversial because previous studies have included patients with other risk factor for ED.
  
  
  OBJECTIVE
  To determine if the treatment with allopurinol improved endothelial function in hyperuricemic patients without other risk factors for ED.
  
  
  METHODS
  In order to gain more insight about the contribution of UA to the ED, we screened 369 apparently healthy male individuals for UA in a period of 9 months. Only 9 patients fulfill the inclusion criteria: UA plasma levels > 7 mg/dL without other risk factors for ED such as hypercholesterolemia, obesity, diabetes and hypertension.
  
  
  RESULTS
  Endothelial function, assessed by flow mediated dilatation (FMD) in the brachial artery improved significantly after 30 days of allopurinol treatment (9.6% [6.3-13.3%] vs. 13.7% [11-14.7%], p = 0.036), concomitantly with a decrease of about 45% in the uric acid plasma levels. Other parameters were not modified by allopurinol treatment. Any No significant correlation was found (r = -0.367, p = 0.33) between the ΔUA plasma levels (UA after treatment - UA in basal conditions) and ΔFMD (FMD after treatment - FMD in basal conditions).
  
  
  CONCLUSIONS
  These results strongly suggest that allopurinol improves flow-mediated vasodilation regardless of uric acid plasma concentrations.
authors: Department of Magnetic Resonance, Instituto Nacional de Cardiología, Ignacio Chávez , Mexico City , Mexico.
authors: Gabriela
authors: G
authors: Meléndez-Ramírez
authors: Oscar
authors: O
authors: Pérez-Méndez
authors: Cristhel
authors: C
authors: López-Osorio
authors: Jorge
authors: J
authors: Kuri-Alfaro
authors: Nilda
authors: N
authors: Espinola-Zavaleta
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000494:pharmacology* / Q000627:therapeutic use; D001916:Brachial Artery / Q000187:drug effects / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D006074:Gout Suppressants / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood; D014664:Vasodilation / Q000187:drug effects* / Q000502:physiology
chemical_list: D006074:Gout Suppressants; D014527:Uric Acid; D000493:Allopurinol